Cape Town – Diabetes, long eclipsed by infectious diseases, has now surpassed tuberculosis (TB) as the leading cause of death in South Africa, a shift scientists are calling “a national emergency.”
According to the latest Statistics South Africa Causes of Death Report, deaths from non-communicable diseases rose by 58.7% between 2002 and 2022, with diabetes emerging as the country’s top killer, overtaking TB.
These figures took centre stage at the inaugural Cardio-Kidney-Metabolic (CKM) Africa Summit 2025, which wrapped up in Cape Town this past weekend. The event brought together 350 healthcare professionals in person, with 400 joining online from across Africa.
Experts at the CKM Summit emphasised that managing type 2 diabetes in isolation is no longer enough.
A broader focus is needed, linking diabetes treatment to obesity, cardiovascular complications, kidney disease, and other metabolic disorders.
The old mantra of “eat less and exercise more” is no longer sufficient science in the face of the modern epidemic of obesity, type 2 diabetes, and related conditions, scientists insisted.
Thabeng Charles Leping, Director of Market Access and Public Affairs, Commercial Affairs and Strategy at Novo Nordisk, said the CKM Summit 2025 highlighted new technologies and treatment regimens already delivering promising results.
“Partnerships are essential,” Leping told journalists. “We need to ensure that innovations available in the private sector reach broader communities.
“It’s about using our strengths to make these therapies widely accessible.”
He revealed that the CKM Summit is the brainchild of Novo Nordisk, a Danish pharmaceutical giant renowned for pioneering diabetes care, obesity treatment, and chronic disease management. It serves patients in over 170 countries.
Novo Nordisk plays a significant role in South Africa’s public and private health sectors, “supplying vital diabetes medicines and driving awareness campaigns,” he said.
He emphasised that the company focuses on “partnerships that expand patient access and tackle the rising burden of non-communicable diseases like diabetes, obesity, and cardiovascular conditions.”
At the 85th American Diabetes Association (ADA) Congress, held in Chicago from 21 to 24 June 2025, Novo Nordisk proved its mettle for research innovation and patient-centred care, reaffirming its place at the forefront of tackling global health challenges.
Working alongside international researchers, Novo Nordisk unveiled fresh findings from the STEP-UP trial, which tested a higher dose of semaglutide, the active ingredient in the weight-loss drug Wegovy and the type 2 diabetes treatment Ozempic.
The trial focused on people living with obesity, but who did not have diabetes.
Results showed that a 7.2-milligram dose led to an average weight loss of 21 per cent over 72 weeks, with one-third of participants shedding at least 25 per cent of their body weight.
The safety profile remained consistent with earlier semaglutide studies, with most side effects limited to mild to moderate gastrointestinal symptoms that resolved over time.
Novo Nordisk plans to seek a label update for this higher dose in the European Union and other markets where Wegovy has already been approved.
CKM Summit Calls for a Broader View of Diabetes Care
A panel at the CKM Summit explored diabetes within cardiometabolic health.
It featured Dr Zaheer Bayat, a specialist physician and endocrinologist, and Head of Internal Medicine at Helen Joseph Hospital, an academic hospital linked to the University of the Witwatersrand, who chaired the session.
The panel included Professor Samir Naim Assad, an Egyptian scholar in Internal Medicine and Endocrinology, and Dr Reyna Daya, Clinical Head of Endocrinology at Helen Joseph Hospital and executive of the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA).
Prof Magdy Helmy Megallaa, Professor of Internal Medicine and Diabetes at Alexandria University in Egypt and Honorary Lecturer at Cardiff University, UK, also contributed insights.
These experts warned that diabetes significantly raises the risk of cardiovascular disease (CVD), even without classic dangers like high blood pressure or smoking.
Diabetes can elevate CVD risk up to 30 years before diagnosis, doubling the chances of cardiovascular events.
The discussion covered how diabetes influences heart failure, strokes, and peripheral artery disease, conditions responsible for a quarter of CVD deaths.
Speakers stressed the need to manage diabetes, hypertension, and lifestyle factors and explored new drugs like Glucagon-like peptide-1 (GLP-1) agonists for CVD prevention.
They also noted that CVD itself can trigger diabetes, recommending thorough screening for those at high risk.
New Drugs Bring Hope for Heart and Kidney Protection
Speaking at the plenary session titled Connecting the Dots, Professor Hani Sabbour, Consultant Cardiologist and Electrophysiologist at Cleveland Clinic Abu Dhabi and Clinical Assistant Professor at Brown University, shared insights on new strategies in diabetes care.
“We now focus on cardiovascular and kidney protection therapies, not just glucose levels,” said Sabbour.
He explained that updated guidelines support early use of GLP-1 receptor agonists and Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), even before metformin, tailored to each patient’s risk profile.
Prof Sabbour highlighted that chronic kidney disease significantly raises cardiovascular risks in people with diabetes.
“This marks a significant shift in how we treat patients with diabetes,” he noted.
He emphasised the value of comprehensive screening, lifestyle changes, and advanced therapies.
“Our goal is holistic care that tackles diabetes, heart disease, and kidney complications together,” he said.
Professor Arya M. Sharma, Professor Emeritus of Medicine and former Canada Research Chair in Obesity Research and Management at the University of Alberta, Canada, founded Obesity Canada and led it as its first Scientific Director.
Professor Sharma challenged common beliefs about weight gain.
“Some people are naturally slender, but most sit on a spectrum where genetics and biology dictate weight gain, even with identical diets and activity levels,” he said.
He noted that factors like social pressures, diseases, medications, and emerging research on the microbiome and endocrine disruptors all play a role.
Why Weight Gain Isn’t Just About Willpower?
He stressed that blaming people for eating too much misses the point.
“That’s like saying someone’s depressed because they’re unhappy,” he explained.
He described the brain’s powerful homeostatic system, designed to defend body weight against loss.
“The minute you stop dieting, your weight fights to return,” he said.
He added that another brain system, the hedonic or reward system, drives eating for pleasure rather than hunger, making sustained weight loss a complex battle against deeply rooted biology.
Unsurprisingly, consensus has emerged within the scientific community that obesity is a medical condition demanding a multidisciplinary approach.
“Pharmacological solutions now stand at the forefront of medical care, alongside lifestyle changes and patient-centred support,” scientists concluded.


